

Contents

List of Contributors XIII

Preface XVII

A Personal Foreword XIX

- 1 Outlook of the Antiviral Drug Era, Now More Than 50 Years After Description of the First Antiviral Drug** 1
Erik De Clercq
- 1.1 Introduction: The Prehistory 1
- 1.2 Key Events in Antiviral Drug Development 2
- 1.3 Antiviral Drugs: Current State of the Art 4
- 1.4 Antiviral Drugs Active against Herpesviruses (i.e., HSV, VZV, and so on) 4
- 1.5 Antiviral Drugs Active against Retroviruses (HIV) 8
- 1.6 Antiviral Drugs Active against Hepatitis B Virus 12
- 1.7 Antiviral Drugs Active against DNA Viruses at Large 13
- 1.8 Antiviral Drugs for Influenza A Virus Infections 14
- 1.9 Antiviral Drugs for Hepatitis C Virus 15
- 1.10 Antiviral Drugs for Poxviruses (i.e., Variola, Vaccinia, and so on) 17
- 1.11 Further Options to Treat Virus Infections 19
- 1.12 Conclusions 19
References 20
- 2 Inhibition of HIV Entry** 29
José A. Esté
- 2.1 Introduction 29
- 2.2 The HIV Glycoproteins 30
- 2.2.1 Structure of the HIV-1 Glycoprotein gp120 30
- 2.2.2 Structure of the HIV-1 Transmembrane Glycoprotein gp41 31
- 2.3 Mechanism of HIV Entry 32
- 2.3.1 Virus Attachment 32
- 2.3.2 Coreceptors: Virus Tropism and Infectivity 33

2.3.3	Virus–Cell Fusion	33
2.3.4	Endocytosis of HIV	33
2.4	Inhibition of HIV Entry	34
2.4.1	Inhibitors of Virus Attachment	34
2.4.1.1	Polyanions as Inhibitors of HIV Attachment	34
2.4.1.2	Small-Molecule Inhibitors of the gp120–CD4 Interaction	36
2.4.2	Postattachment Inhibitors	37
2.4.3	CCR5 Antagonists	38
2.4.3.1	Maraviroc	38
2.4.3.2	Vicriviroc	39
2.4.3.3	Pro-140	39
2.4.3.4	Resistance to CCR5 Antagonists	39
2.4.4	CXCR4 Antagonists	40
2.4.5	Inhibitors of HIV Fusion: Enfuvirtide	41
2.5	Concluding Remarks	42
	References	42

3 Targeting Integration Beyond Strand Transfer: Development of Second-Generation HIV Integrase Inhibitors 51

Arnout R.D. Voet, Marc De Maeyer, Frauke Christ, and Zeger Debyser

3.1	HIV: The Causative Agent of AIDS	51
3.1.1	Replication Cycle of HIV	51
3.1.2	Highly Active Antiretroviral Therapy	52
3.2	The Integration Step: A Complex Mechanism with Different Possibilities for Inhibition	53
3.2.1	HIV-1 Integrase	53
3.2.1.1	The Structural Organization of HIV-1 Integrase	54
3.2.2	HIV-1 IN as a Target for HAART	55
3.2.2.1	Integrase Strand Transfer Inhibitors	55
3.2.2.2	Integrase Binding Inhibitors	57
3.3	DNA Binding Inhibitors	59
3.4	Multimerization Inhibitors	60
3.5	Targeting Integrase Cofactor Interactions	62
3.6	Conclusion	64
	References	65

4 From Saquinavir to Darunavir: The Impact of 10 Years of Medicinal Chemistry on a Lethal Disease 73

Marie-Pierre de Béthune, Anik Peeters, and Piet Wigerinck

4.1	Introduction	73
4.2	The HIV Protease as a Target for AIDS	73
4.3	The Early Protease Inhibitors	74
4.4	The Medical Need for a “Next”-Generation PI	78
4.5	How Can We Explain the Superior Antiviral Activity of Darunavir?	85

4.6	Clinical Development of Darunavir	86
4.7	Conclusions and Future Developments	87
	References	87
5	Acyclic and Cyclic Nucleoside Phosphonates	91
	<i>Richard L. Mackman and Tomas Cihlar</i>	<i>91</i>
5.1	Introduction	91
5.2	Nucleoside Phosphonate Strategy for Antivirals	92
5.3	Acyclic Nucleoside Phosphonates	95
5.3.1	Main Classes and their Structure–Activity Relationships	95
5.3.1.1	HPMP Analogues	95
5.3.1.2	PME Analogues	95
5.3.1.3	PMP and FPMP Analogues	97
5.3.2	Additional Examples of Antiviral ANPs	98
5.4	Cyclic Nucleoside Phosphonates	99
5.4.1	Main Classes and their Structure–Activity Relationships	100
5.4.1.1	Tetrahydrofuran Core	100
5.4.1.2	Cyclopentane and Cyclopentene Cores	103
5.4.2	Examples of CNPs Targeting Viral RNA Polymerases	104
5.5	Prodrugs of Nucleoside Phosphonates	107
5.5.1	Phosphonoesters	107
5.5.2	Phosphonoamidates	109
5.6	Clinical Applications of Antiviral Nucleoside Phosphonates	111
5.6.1	Cidofovir (Vistide [®])	112
5.6.2	Adefovir Dipivoxil (Hepsera [®])	112
5.6.3	Tenofovir Disoproxil Fumarate (Viread [®])	113
5.7	Conclusions	115
	References	115
6	Helicase–Primase Inhibitors: A New Approach to Combat Herpes Simplex Virus and Varicella Zoster Virus	129
	<i>Subhajit Biswas and Hugh J. Field</i>	
6.1	Introduction	129
6.2	The Role of Helicase Primase in the Replication of HSV	130
6.3	Selective Inhibitors of Helicase Primase as Antiherpesvirus Antivirals	131
6.4	HPIs are Effective in Cell Culture and <i>In Vivo</i>	133
6.5	Effects of HPIs on the Establishment and Reactivation from Latency	134
6.6	HPIs: The Biochemical Basis for the Proposed Mechanism of Action	134
6.7	HSV Acquired Resistance to HPIs	135
6.8	Patterns of Cross-Resistance	136
6.9	Further Insight into Mode of HPI Interaction with the HSV HP Complex from the Study of Resistance Mutations	139

6.10	The Frequency and Origin of HPI-Resistance Mutations	140
6.11	UL5 Lys356Asn: a Mutation Conferring High Resistance to HPI	141
6.12	The Origin of Resistance Mutations at High Frequency	142
6.13	Conclusions	142
	References	144
7	Cyclophilin Inhibitors	147
	<i>Grégoire Vuagniaux, Arnaud Hamel, Rafael Crabbé, Hervé C. Porchet, and Jean-Maurice Dumont</i>	
7.1	Introduction	147
7.2	Cyclophilin Overview	148
7.3	Cyclophilin Inhibitors Currently in Clinical Development	148
7.3.1	Chemical Structure	149
7.3.2	CypA PPIase Inhibition and Lack of Immunosuppressive Activity	149
7.4	Cyclophilin and HIV	149
7.4.1	Cyclophilin Inhibitors against HIV-1	151
7.4.1.1	<i>In Vitro</i> Anti-HIV-1 Activity	151
7.4.1.2	Resistance Profile	152
7.4.1.3	<i>In Vivo</i> Activity	152
7.4.1.4	Putative Mechanism of Action of Cyclophilin Inhibitors against HIV-1	152
7.4.1.5	Clinical Activity of Debio 025 against HIV-1	153
7.4.2	No Activity against Simian Immunodeficiency Virus	154
7.4.3	Activity against HIV-2	154
7.5	Cyclophilin and Hepatitis C	155
7.5.1	Putative Role of Cyclophilin in HCV Replication	155
7.5.2	Activity of Cyclophilin Inhibitors in HCV	157
7.5.3	Resistance Profile	158
7.6	Clinical Results in HCV	159
7.6.1	Debio 025	159
7.6.1.1	Randomized, Double-Blind, Placebo-Controlled Study in HIV-1/HCV Coinfected or HIV-1 Monoinfected Patients	159
7.6.1.2	Randomized, Double-Blind, Placebo-Controlled, Escalating Dose Ranging Study of Debio 025 in Combination with Pegasys in Treatment-Naïve Patients with Chronic Hepatitis	159
7.6.2	Study of Debio 025 in Combination with PEG-IFN α 2 and Ribavirin in Chronic HCV Genotype 1 Nonresponding Patients	162
7.6.3	Adverse Events	167
7.6.4	NIM811 and SCY635	167
7.7	Activity against Other Viruses	167
7.8	New Noncyclosporine Cyclophilin Inhibitors	168
7.8.1	Peptides and Peptidomimetics	168
7.8.2	CsA Bis-Urea Derivatives	169
7.8.3	Dimedone-Like Molecules	169

7.8.4	Quinoxaline Derivatives	169
7.8.5	Diarylurea Derivatives	170
7.8.6	Other Acylurea Derivatives	171
7.9	Conclusion	173
	References	173
8	Alkoxyalkyl Ester Prodrugs of Antiviral Nucleoside Phosphates and Phosphonates	181
	<i>James R. Beadle and Karl Y. Hostetler</i>	
8.1	Introduction	181
8.2	Enhancing the Oral Activity of Antiviral Compounds: Overview of the Development of Alkoxyalkyl Esterification Approach	182
8.3	Alkylglycerol and Alkoxyalkyl Prodrugs of Phosphonoformate: Enhanced Antiviral Activity and Synergism with AZT	185
8.4	Alkoxyalkyl Esters of Nucleoside 5'-Monophosphates	185
8.5	Oral Prodrugs of Acyclic Nucleoside Phosphonates	189
8.5.1	Cidofovir	189
8.5.1.1	Activity against Poxviruses <i>In Vitro</i>	189
8.5.1.2	Activity against Other Double-Stranded DNA Viruses <i>In Vitro</i>	190
8.5.1.3	Efficacy of Alkoxyalkyl Esters of ANPs in Animal Models of Disease	191
8.5.2	Alkoxyalkyl Esters of (S)-HPMPA	191
8.5.3	Alkoxyalkyl Esters of Tenofovir (HDP-(R)-PMPA)	196
8.5.4	Hexadecyloxypropyl Adefovir and Prodrugs of Other ANPs and Antivirals	197
8.6	Intraocular Delivery of Antiviral Prodrugs for Treatment or Prevention of Cytomegalovirus Retinitis	198
8.6.1	1-O-Octadecyl- <i>sn</i> -glycero-3-phosphonoformate (ODG-PFA)	198
8.6.2	Hexadecyloxypropyl Ganciclovir 5'-Monophosphate (HDP-P-GCV)	199
8.6.3	Hexadecyloxypropyl Esters of Cyclic Cidofovir and Cyclic (S)-HPMPA	200
8.7	Conclusion	201
	References	201
9	Maribavir: A Novel Benzimidazole Ribonucleoside for the Prevention and Treatment of Cytomegalovirus Diseases	209
	<i>Karen K. Biron</i>	
9.1	Cytomegalovirus Diseases: Unmet Challenges	209
9.2	Maribavir: Antiviral Activity	210
9.3	Maribavir: Mechanisms of Action and Resistance	212
9.4	Preclinical Studies	214
9.5	Clinical Development of Maribavir: Early Phase I	215
9.6	Clinical Development in a Transplant Population	218

9.7	Summary and Conclusions	220
	References	221
10	Anti-HCMV Compounds	227
	<i>Graciela Andrei and Robert Snoeck</i>	
10.1	Introduction	227
10.2	Anti-HCMV Drugs in Clinical Use	229
10.2.1	Classes of Anti-HCMV Drugs	229
10.2.2	Toxicity Associated with Approved Anti-HCMV Drugs	231
10.2.3	Resistance to Anti-HCMV Antivirals	233
10.3	Need for New Anti-HCMV Drugs	234
10.4	Novel Viral Targets	235
10.4.1	Viral Entry Inhibitors	235
10.4.1.1	β -Peptides	235
10.4.1.2	Dendrimers	235
10.4.1.3	Amphipathic DNA Polymers	237
10.4.1.4	Thiourea Derivatives	237
10.4.1.5	Phosphorothioate-Modified Oligonucleotides	237
10.4.2	Inhibitors of Viral Genome Replication	238
10.4.2.1	DNA Polymerase Inhibitors	238
10.4.2.2	Helicase/Primase Inhibitors	245
10.4.2.3	Inhibitors of Protein-Protein Interactions	246
10.4.3	Viral Gene Expression Inhibitors	248
10.4.3.1	Small Interfering RNAs	248
10.4.4	Inhibitors of Virion Assembly and Egress	248
10.4.4.1	Inhibitors of DNA Cleavage/Packaging	248
10.4.4.2	UL97 Protein Kinase (pUL97) Inhibitors	252
10.4.4.3	Viral Protease Inhibitors	256
10.4.5	Additional New Inhibitors of HCMV	256
10.4.5.1	Agonist for HCMV-Encoded Chemokine Receptors	256
10.4.6	HCMV Inhibitors with a Mechanism of Action not Fully Unraveled	258
10.4.6.1	CMV423	258
10.4.6.2	Berberine Chloride, Arylsulfone Derivatives, Lipophilic Alkyl Furano Pyrimidine Dideoxy Nucleosides, and 4''-Benzoyl-Ureido-TSAO Derivatives	258
10.4.6.3	Leflunomide	259
10.4.6.4	Artesunate	260
10.5	Cellular Targets	260
10.5.1	Inhibitors of Cyclin-Dependent Kinases	261
10.5.2	Inhibitors of Cyclooxygenase 2	262
10.5.3	Proteasome Inhibitors	263
10.6	Conclusions	265
	References	266

11	Lethal Mutagenesis as an Unconventional Approach to Combat HIV	283
	<i>Pinar Iyidogan and Karen S. Anderson</i>	
11.1	Introduction	283
11.2	Viral Fitness and Intrinsic Mutagenesis in RNA Viruses and Retroviruses	284
11.3	Fundamentals of Lethal Mutagenesis	286
11.4	Mutagenic Pharmaceuticals as Antiviral Agents	288
11.4.1	Ribavirin	288
11.4.2	5-OH-dC	290
11.4.3	5-AZC	291
11.5	KP-1212: From Bench to Clinic	292
11.6	Challenges and Advantages of Lethal Mutagenesis Compared to Conventional Strategies	294
11.7	Concluding Remarks and Future Perspectives	296
	References	298
12	Recent Progress in the Development of HCV Protease Inhibitors	307
	<i>Nagraj Mani, Bhisetti G. Rao, Tara L. Kieffer, and Ann D. Kwong</i>	
12.1	Introduction	307
12.2	HCV Therapy	307
12.2.1	The Role of HCV Protease	308
12.2.2	HCV Protease Inhibitor Design	310
12.2.3	Similarities and Differences in HCV Protease Inhibitors	310
12.2.4	Antiviral Potency and the Emergence of Resistance	316
12.3	Mechanism of Resistance and Cross-Resistance to NS3 Protease Inhibitors	316
12.3.1	Pattern of Resistance to Covalent Linear Protease Inhibitors	316
12.3.2	Pattern of Resistance to Noncovalent Protease Inhibitors	318
12.3.3	Cross-Resistance between Linear and Macrocylic HCV Protease Inhibitors	318
12.4	Antiviral Potency and Clinical Efficacy of HCV Protease Inhibitors	319
12.4.1	Telaprevir	319
12.4.2	Boceprevir	320
12.4.3	Safety Profile of Protease Inhibitors	321
12.5	Future Directions	321
	References	322
13	Antiviral RNAi: How to Silence Viruses	329
	<i>Karin J. von Eije and Ben Berkhout</i>	
13.1	The Discovery of RNA Interference	329
13.2	Therapeutic Application of the RNAi Mechanism	329
13.3	Mammalian Viruses and the RNAi Mechanism	331

13.4	Basic Design of an RNAi Therapy against Viruses	332
13.5	Selecting Optimal Targets	332
13.6	Prevention of Viral Escape	334
13.7	Multiplexing siRNAs	335
13.8	Delivery Issues	335
13.9	Potential Risks of an RNAi Therapy	336
13.10	Example of an Acute Infection: RSV	337
13.11	Example of a Chronic Infection: HIV-1	337
13.12	Future Perspective	338
	References	340
14	Neuraminidase Inhibitors as Anti-Influenza Agents	351
	<i>Willard Lew, Michael Z. Wang, Xiaowu Chen, James F. Rooney, and Choung Kim</i>	
14.1	Introduction	351
14.2	Influenza Neuraminidase as a Drug Target	353
14.3	Neuraminidase Active Site and Inhibitor Binding	354
14.4	Small-Molecule Inhibitors of Influenza Neuraminidase	355
14.4.1	Zanamivir (Relenza) and Related Compounds	355
14.4.2	Laninamivir (CS-8958): A Long-Acting Neuraminidase Inhibitor	358
14.4.3	Oseltamivir (Tamiflu)	359
14.5	Mechanism of Resistance	364
14.6	Influenza Neuraminidase Inhibitors Based on Other Scaffolds	364
14.6.1	Peramivir (BCX-1812, RWJ-270201)	364
14.6.2	ABT-675	366
14.7	Clinical Use of Neuraminidase Inhibitors	367
14.8	Concluding Remarks	369
	References	370
15	From TIBO to Rilpivirine: The Chronicle of the Discovery of the Ideal Nonnucleoside Reverse Transcriptase Inhibitor	377
	<i>Erik De Clercq</i>	
15.1	Introduction	377
15.2	The TIBO Derivatives	378
15.3	From Loviride to Rilpivirine	380
15.4	Rilpivirine: How Does It Act?	381
15.5	Clinical Proof of Concept	383
15.6	Pharmacokinetics and Drug–Drug Interactions	383
15.7	Potency and Resilience to NNRTI Resistance	384
15.8	Conclusion	385
	References	385